Novoron Bioscience

Novoron Bioscience

Novoron Bioscience, Inc was founded in February 2013 and is a biotechnology company focused on developing pharmaceutical therapies for nerve regeneration in the central nervous system (CNS); specifically, spinal cord injury (SCI). Novoron is a Delaware C-corp and our home is in San Diego, California. We were founded on the graduate thesis work of our President and CEO, Travis L. Stiles, Ph.D. While at the University of California, San Diego, Travis discovered that Low-Density Lipoprotein receptor-related protein (LRP1) is a novel receptor for molecular components of degraded myelin – myelin associated inhibitors (MAIs) – which are a major obstacle to the ability of the CNS to regenerate. LRP1 is a potent facilitator of the inhibitory actions of MAIs, which indicates that LRP1 may be the key to overcoming one of the major obstacles to regeneration of neurons following SCI. Blocking LRP1/MAI interactions with the LRP1 antagonist receptor associated protein (RAP) restores the growth capacity of neurons in the presence of MAIs. This published, patent-protected discovery (U.S. Provisional Patent 61/479,210; PCT application filed in April 2012) is the technological-foundation of Novoron.

Area of focus: 
Neuroscience
Commencement date: 
09/22/2014

Share